Author Archives: Bruno Quinney

ulcerative colitis
#Crohn's disease #Inflammatory Bowel Disease #NHS Scotland #Ulcerative colitis (UC)

Inflammatory bowel disease drug approved for use in NHS Scotland 

The Scottish Medicines Consortium (SMC) has accepted Tremfya (guselkumab) for use in NHS Scotland for the treatment of adult patients with moderately to severe Crohn’s disease and ulcerative colitis.  Guselkumab is the first IL-23 inhibitor that could offer a fully subcutaneous induction and maintenance regimen in Crohn’s disease and ulcerative… Read More

#News #Regulatory

#Cell Science #Drug discovery #Organoids #Protein #Stem cells #Vaccines

How new scientific approaches are accelerating R&D

This is the latest episode of the free DDW Narrated Podcast, called “How new scientific approaches are accelerating R&D”. The episode covers two articles written for DDW Volume 25, Issue 1, Winter 2023/24. The first article is called ‘Accelerating recombinant protein vaccine discovery’. In the… Read More

#Featured Podcasts #Podcasts

#Acute Myeloid Leukaemia #Cancer research #Leukaemia #Oncology #Syndax Pharmaceuticals

Leading the charge in cancer care

DDW Editor Reece Armstrong speaks to Michael Metzger, CEO of Syndax, about its work on developing therapeutics for challenging cancer targets.    RA: What are the unmet needs in relapsed or refractory acute leukaemia. How great is this unmet need in paediatric patients?   MM: Syndax is initially focused on two… Read More

#Exclusive Content

Genome editing concept
#Bacteriophage #Genome editing #Synthetic DNA

New method shows ‘sky’s the limit’ for genome editing 

Scientists have developed a new method to construct bacteriophages with entirely synthetic genetic material, allowing them to edit genomes gene by gene.  Researchers at the University of Pittsburgh, US, led by Graham Hatfull, developed the method to add and subtract genes from the synthetic genome at will. Read More

#News

#Anti-inflammatory #Clinical trial #Immunology

Apogee Therapeutics announces positive data for I&I antibody 

Biotechnology company Apogee Therapeutics has announced positive Phase I data for its antibody APG333.  APG333, a novel half-life extended TSLP antibody, has been developed for inflammatory and immunology (I&I) markets. In the double-blind, placebo-controlled, first-in-human Phase I clinical trial, APG333 was well tolerated across all cohorts of… Read More

#News

#Business #Eli Lilly #MeiraGTx #Ophthalmology

MeiraGTx partners with Eli Lilly in ophthalmology 

Genetic medicines company MeiraGTx has announced a strategic partnership with Eli Lilly to develop and commercialise genetic medicines in ophthalmology.  The deal, worth $475 million, will see MeiraGTx grant Lilly worldwide exclusive rights to its AAV-AIPL1 programme for treatment of Leber congenital amaurosis 4 (LCA4). LCA4 is one of the… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Business #Clinical development #Financing

myTomorrows to use funding to ‘transform’ patient therapy access 

Health technology company myTomorrows has secured $29 million in funding to develop its AI-driven global platform, aiming to bring patients access to innovative therapies.  The company aims to develop a platform to bridge the gap between scientific advancement and patient access to pre-approval treatments. This includes drug candidates undergoing clinical… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Computer modelling #Drug discovery

Moving towards a golden age of drug discovery

Rajesh Kumar, Senior Director of Structural Biology at Schrodinger, shares with Diana Turner how advanced computational models are supercharging modern drug discovery and the impact they could have in the future.    DT: Can you tell us a bit more about Schrödinger and what you do? RK: Schrödinger’s (SDGR) core… Read More

#Exclusive Content

#Animal models #In vitro #Innovate UK #UK government

Initiative aims to replace animal models for drug development 

A new UK initiative is aiming to transform human-based research models to provide better understanding of disease and accelerate new medicines.   The UKRI Medical Research Council (MRC), Wellcome and UKRI Innovate UK committed a joint £15.9 million ($20.9 million) investment to develop advanced, specific and highly reproducible… Read More

#Editor's Choice #News

Hepatitis virus
#Bluejay Therapeutics #Clinical trial #hepatitis

Hepatitis D drug achieves 100% virologic response 

Biopharmaceutical company Bluejay Therapeutics’ hepatitis drug candidate has achieved a 100% virologic response at week 48 of clinical trials.  Brelovitug, an investigational, fully human, high-affinity monoclonal antibody (mAb), targets hepatitis B virus surface antigen (anti-HBsAg) in chronic hepatitis D (CHD). The company announced brelovitug achieved 100%… Read More

#News

Female researcher in a laboratory
#Artificial intelligence (AI) #Drug discovery #Eli Lilly #Insilico Medicine

Insilico partners with Eli Lilly on AI drug discovery 

Drug discovery company Insilico Medicine has entered a research collaboration with pharmaceutical giant Eli Lilly to advance AI-driven drug discovery.  Insilico will use its validated Pharma.AI platform to generate, design, and optimise candidate compounds against targets defined under the agreement.   The company is eligible to receive over $100 million including… Read More

#Business & Investment #News

#Biopharma #Business #Duchenne muscular dystrophy #Immunology / Virology & Vaccines #Mitochondria #Obesity

DDW Highlights: 11 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s leading story came from a positive development in biopharma, with top companies… Read More

#Podcasts

#DNA #Drug discovery #Single-cell analysis

New insight into DNA function offers hope for drug discovery

Scientists have captured the most detailed view yet of how DNA folds and functions inside living cells, which could provide new insights into gene regulation.  Researchers at the Radcliffe Department of Medicine, University of Oxford, used a new technique called MCC Ultra to map the human genome down to a… Read More

#News

#Biopharma #Business #Duchenne muscular dystrophy #Immunology / Virology & Vaccines #Mitochondria #Obesity

This week in Drug Discovery (3 – 7 November) 

News round-up for 3 – 7 November by Bruno Quinney, Content Team at DDW.    This week’s leading story is a positive development in biopharma, with top companies reporting market growth in Q3 of 2025. Elsewhere, new research could help combat yellow fever and weight loss, while £500,000 was awarded to a… Read More

#News

T cell therapy in lupus
#Biotech #Business #Cell therapy

Cue Biopharma and ImmunoScape partner on cell therapies 

Biotechnology companies Cue Biopharma and ImmunoScape have entered into a collaboration and license agreement to advance cell therapies for the treatment of solid tumours.  Under the agreement, ImmunoScape will develop a novel ‘Seed-and-Boost’ immunotherapy that combines Cue Biopharma’s clinically-validated Immuno-STAT T-cell engagers with ImmunoScape’s proprietary TCRs. The combination therapy is designed to overcome core limitations of existing cell therapies with the potential… Read More

#Business & Investment #News